1 1
Out of Stock

Wegovy (Semaglutide) Injection Pen 0.5 mg, 1 Ct - Novo Nordisk

Wegovy (Semaglutide) Injection Pen 0.5 mg, 1 Ct - Novo Nordisk

PKR 31,945
PKR 31,945
Out of Stock
Pack Size: 1 x 1.5mL pen & 4 disposable needles
Wegovy (semaglutide) is a prescription GLP‑1 receptor agonist indicated for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight‑related...  Read More
Brand: Novo Nordisk
SKU: 05712249133030
Availability: In Stock
Country: Pakistan
View full details

Description

Wegovy (semaglutide) is a prescription GLP‑1 receptor agonist indicated for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight‑related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia). Administered once weekly subcutaneously, it works by reducing appetite and slowing gastric emptying. Wegovy is also indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non‑fatal myocardial infarction, or non‑fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.

  • Clinically Proven Weight Loss: The 2.4 mg maintenance dose produced a mean weight loss of up to 15.6% in the STEP UP trial, with the 0.5 mg dose helping to build tolerance during the initial titration phase.
  • Reduces Cardiovascular Risk: The SELECT trial demonstrated that semaglutide 2.4 mg reduced the relative risk for major adverse cardiovascular events by 20% compared with placebo in adults with established cardiovascular disease and BMI ≥27 kg/m²
  • Convenient Once‑Weekly Dosing: Inject subcutaneously once weekly in the abdomen, thigh, or upper arm, at any time of day, with or without meals

Composition
Each prefilled pen contains 2 mg semaglutide in 1.5 mL (1.34mg/mL)

Directions for Use

  • Use as prescribed by the physician.

Legal Disclaimer

Unless expressly indicated in the product description, MyVitaminStore.pk is not the manufacturer of the products sold on our website. While we work to ensure that product information on our website is correct, manufacturers may alter their product information. Actual product packaging and materials may contain more and/or different information than shown on our website. If you have any specific product queries, please contact the manufacturer. For medicinal products, content on our website is not intended to be used to diagnose, treat, cure, or prevent any disease or health condition or to substitute advice given by medical practitioners, pharmacists or other licensed health care professionals. You should contact your health care provider immediately if you suspect that you have a medical problem. You should always read the labels, warnings and instructions provided with the product before using or consuming it and not solely rely on the information presented on our website.

Product Overview

Wegovy (semaglutide) is a prescription GLP‑1 receptor agonist indicated for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight‑related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia). Administered once weekly subcutaneously, it works by reducing appetite and slowing gastric emptying. Wegovy is also indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non‑fatal myocardial infarction, or non‑fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.

  • Clinically Proven Weight Loss: The 2.4 mg maintenance dose produced a mean weight loss of up to 15.6% in the STEP UP trial, with the 0.5 mg dose helping to build tolerance during the initial titration phase.
  • Reduces Cardiovascular Risk: The SELECT trial demonstrated that semaglutide 2.4 mg reduced the relative risk for major adverse cardiovascular events by 20% compared with placebo in adults with established cardiovascular disease and BMI ≥27 kg/m²
  • Convenient Once‑Weekly Dosing: Inject subcutaneously once weekly in the abdomen, thigh, or upper arm, at any time of day, with or without meals

Composition
Each prefilled pen contains 2 mg semaglutide in 1.5 mL (1.34mg/mL)

Directions for Use

  • Use as prescribed by the physician.

Legal Disclaimer

Unless expressly indicated in the product description, MyVitaminStore.pk is not the manufacturer of the products sold on our website. While we work to ensure that product information on our website is correct, manufacturers may alter their product information. Actual product packaging and materials may contain more and/or different information than shown on our website. If you have any specific product queries, please contact the manufacturer. For medicinal products, content on our website is not intended to be used to diagnose, treat, cure, or prevent any disease or health condition or to substitute advice given by medical practitioners, pharmacists or other licensed health care professionals. You should contact your health care provider immediately if you suspect that you have a medical problem. You should always read the labels, warnings and instructions provided with the product before using or consuming it and not solely rely on the information presented on our website.

Product Overview

Wegovy (semaglutide) is a prescription GLP‑1 receptor agonist indicated for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight‑related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia). Administered once weekly subcutaneously, it works by reducing appetite and slowing gastric emptying. Wegovy is also indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non‑fatal myocardial infarction, or non‑fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.

  • Clinically Proven Weight Loss: The 2.4 mg maintenance dose produced a mean weight loss of up to 15.6% in the STEP UP trial, with the 0.5 mg dose helping to build tolerance during the initial titration phase.
  • Reduces Cardiovascular Risk: The SELECT trial demonstrated that semaglutide 2.4 mg reduced the relative risk for major adverse cardiovascular events by 20% compared with placebo in adults with established cardiovascular disease and BMI ≥27 kg/m²
  • Convenient Once‑Weekly Dosing: Inject subcutaneously once weekly in the abdomen, thigh, or upper arm, at any time of day, with or without meals

Composition
Each prefilled pen contains 2 mg semaglutide in 1.5 mL (1.34mg/mL)

Directions for Use

  • Use as prescribed by the physician.

Legal Disclaimer

Unless expressly indicated in the product description, MyVitaminStore.pk is not the manufacturer of the products sold on our website. While we work to ensure that product information on our website is correct, manufacturers may alter their product information. Actual product packaging and materials may contain more and/or different information than shown on our website. If you have any specific product queries, please contact the manufacturer. For medicinal products, content on our website is not intended to be used to diagnose, treat, cure, or prevent any disease or health condition or to substitute advice given by medical practitioners, pharmacists or other licensed health care professionals. You should contact your health care provider immediately if you suspect that you have a medical problem. You should always read the labels, warnings and instructions provided with the product before using or consuming it and not solely rely on the information presented on our website.